



[Redacted text bar]

[Redacted text bar]



[Redacted text bar]




[Redacted text bar]










- Blue bar
- Red bar
- Blue bar
- Blue bar










- Item 1:** A blue bar with a white shadow on a light blue background.
- Item 2:** A blue bar with a white shadow on a light blue background.
- Item 3:** A red bar with a white shadow on a light blue background.
- Item 4:** A blue bar with a white shadow on a light blue background.



?


///

■



?







99.9%
Strut Coverage Rate
at **3 months**¹

0
Def/Prob Stent Thrombosis
at **5 years**²

FIREHAWK™

MicroPort

1 TARGET-III Coroner Trial 3-month OCT follow up results. Presented by William Wyns at EuroPCR 2017.
2 TARGET-III Trial 5-year OCT follow up results. Presented by Huanli Cao at TCT 2016.







2012



2





|

P

L

SI S

| | SI S



SI S

| SI S

SI S

| |






SI S

SI S
SI S

I


L L

? ?

? ?







(USD '000)	2017 1H		
Revenue	217,339	198,556	10%
Cost of sales	(58,995)	(61,595)	-4%
Gross profit	158,344	136,961	16%
Other revenue & net gain	(2,522)	5,084	-150%
Research and development costs	(25,708)	(24,161)	6%
Distribution costs	(63,707)	(62,038)	3%
Administrative expenses	(31,264)	(31,681)	-1%
Other operating costs	(1,098)	(1,728)	-36%
Operating Profit	34,045	22,437	52%
Finance costs	(7,004)	(8,264)	15%
Gain on disposal of subsidiaries	6,531		
Share of losses of JV and associates	(5,811)	(1,768)	
Profit/(loss) before taxation	27,761	12,405	124%
Income tax	(7,147)	(6,870)	4%
Net profit/(loss)	20,614	5,535	272%

|| -

USD'000	30 Jun 2017	31 Dec 2016
Fixed assets	276,143	270,243
Intangible assets	74,044	68,152
Prepayments for fixed assets	2,098	2,010
Goodwill	54,458	54,458
Interest in associate	21,494	11,432
Interest in joint venture	-	676
Available-for-sale financial assets	2,000	2,000
Deferred tax assets	5,272	4,739
Other non-current assets	2,679	3,364
Total Non-current Assets	438,188	417,074
Inventories	110,606	100,863
Trade and other receivables	144,052	128,752
Deposits with banks and investments	803	668
Cash and cash equivalents	103,325	123,694
Derivative financial assets	3,237	3,499
Total Current Assets	362,023	357,476
Total Assets	800,211	774,550
Trade and other payables	(102,852)	(96,858)
Interest-bearing borrowings	(53,776)	(108,456)
Income tax payable	(6,661)	(4,621)
Derivative financial liability	-	(23)
Obligation under finance leases	(48)	(81)
Other current liabilities	-	-
Total Current Liabilities	(163,337)	(210,039)
Interest-bearing borrowings	(42,666)	(40,085)
Convertible bonds	(150,683)	(147,769)
Deferred income	(25,515)	(24,231)
Other payables	(3,708)	(2,664)
Deferred tax liabilities	(3,507)	(3,283)
Total Liabilities	(389,416)	(428,071)
Share capital	(14)	(14)
Reserves	(394,607)	(332,895)
Non controlling interests	(16,174)	(13,570)
Total Equity	(410,795)	(346,479)
Total Liabilities and Equity	(800,211)	(774,550)
Net Assets	410,795	346,479

III- Condensed Consolidated Cash Flow Statement

(USD '000)	2017 1H	2016 1H	Flux %
Cash generate from operations	45,060	38,104	18%
Net income tax paid	(2,727)	(2,381)	15%
Net cash from operating activities	42,333	35,723	19%
Net cash from investing activities	(35,764)	(35,263)	1%
Net cash from financing activities	(28,615)	30,435	-194%
Net movement in cash and cash equivalent	(22,046)	30,895	-171%
Cash and cash equivalents at 1 January	123,694	99,467	24%
Effect of foreign exchange rate changes	1,677	(1,260)	-233%
Cash and cash equivalents at 30 June	103,325	129,102	-20%

Thank You

The Patient Always Comes First

